The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective
Authors:
- 27 April 2015
- journal article
- review article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 26 (5) , 293-304
Abstract
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.Keywords
This publication has 93 references indexed in Scilit:
- Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueGene Therapy, 2012
- Concomitant Intravenous Nitroglycerin With Intracoronary Delivery of AAV1.SERCA2a Enhances Gene Transfer in Porcine HeartsMolecular Therapy, 2012
- SUMO1-dependent modulation of SERCA2a in heart failureNature, 2011
- Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failureGene Therapy, 2011
- SERCA2a controls the mode of agonist-induced intracellular Ca2+ signal, transcription factor NFAT and proliferation in human vascular smooth muscle cellsJournal of Molecular and Cellular Cardiology, 2011
- Epidemiology and risk profile of heart failureNature Reviews Cardiology, 2010
- Organization of Ryanodine Receptors, Transverse Tubules, and Sodium-Calcium Exchanger in Rat MyocytesBiophysical Journal, 2009
- Ion channel regulation of intracellular calcium and airway smooth muscle functionPulmonary Pharmacology & Therapeutics, 2009
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical TrialJournal of Cardiac Failure, 2009
- Molecular ablation of ventricular tachycardia after myocardial infarctionNature Medicine, 2006